730005Negative Chromatography Technology for Cost Effective manufacturing of Antibody BiopharmaceuticalsClosedLegacy RDA Grant for R&DInnovate UKBioToolomics Ltd is a life science company offering cutting-edge solutions to the cost-effective purification of biopharmaceutical drugs. The project is tilted "Negative chromatography technology for the cost-effective manufacturing of antibody biopharmaceuticals". In simple term, according to this technology, an antibody drug produced in cell culture broth is purified by total removal of its surrounding impurities with our selective but inexpensive chromatography media. In contrast, conventional purification technology directly captures antibody drugs with expensive and capacity-limited Protein-A affinity media. With the strong support of two previous Research Grants, BioToolomics has successfully identified the know-hows in making inexpensive process chromatography base matrix, disposable columns and selective mixed-mode ligands. BioToolomics has built up a large library of mixed-mode chromatography media. By coupling the selective mixed-mode ligands to the inexpensive base matrix, very innovative process chromatography products in a ready-to-use disposable format could be developed and deployed in totally new and cost-saving antibody manufacturing processes. Novartis (one of the top five pharmaceutical giants) has agreed to collaborate with BioToolomics to evaluate the technology. We expect to form more collaborations with other big pharmaceutical companies. Therefore, it is the logical decision for BioToolomics to develop the technology towards the market-ready status to harvest its great commercial potential.